Informations générales (source: ClinicalTrials.gov)
Dysbetalipoproteinemia and Atheroma Risk : Assessment of Cardiovascular Risk in Dysbetalipoproteinemic Patients (DARK)
Observational
Hospices Civils de Lyon (Voir sur ClinicalTrials)
janvier 2013
juin 2013
29 juin 2024
Dysbetalipoproteinemia (type III, Fredrickson's classification) is a rare metabolic
disorder. It results from a defect in the clearance of VLDL and chylomicron remnants due
to homozygous APOE2 variants or heterozygous APOE mutations, and there is an elevated
plasma cholesterol and triglycerides.
As a consequence of the derangements in lipoprotein metabolism, dysbetalipoproteinemia
predispose to the premature development of atherosclerosis.
However among this population there is heterogeneity in development of cardiovascular
complications and the determinants remain unclear actually.
The aim of the investigators study is to evaluate the intensity of clinical
atherosclerosis, and identify its determinants.
Etablissements
| Les établissements hors Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| Hospices Civils de Lyon - Groupement Hospitalier Est - 69100 - Bron - France | Philippe MOULIN | Contact (sur clinicalTrials) | |||
Critères
Tous
Inclusion Criteria:
- apo E gene sequencing in CBE (Centre de Biologie Est / Hospices Civils de Lyon /
France) laboratory in Lyon until December 2012
- apo E gene sequencing in CBE (Centre de Biologie Est / Hospices Civils de Lyon /
France) laboratory in Lyon until December 2012
- age < 40 years
- refused participation